The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...

—A large data analysis found a significantly heightened relative risk of optic neuritis in NMOSD, MOGAD, and other inflammatory diseases, supporting prompt evaluation of visual complaints in these ...

In this study, patients have shown good understanding of the symptoms and signs of optic neuritis. The finding that significant increases in the likelihood of patients engaging in best practice in ...

Symptoms of MS may be mild or severe, of long duration or short, and may appear in various combinations, depending on the area of the nervous system affected. Following a relapse, complete or partial ...

Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...